Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On-label paediatric drug product information in Switzerland - the neglected child.

European journal of hospital pharmacy : science and practice·2026
Same author

Social determinants of health and outcome of extremely preterm infants: A Swiss population-based study.

PloS one·2026
Same author

[Impact of psychosocial stress on child development].

Revue medicale suisse·2026
Same author

Paediatric bed capacity in Swiss hospitals: a comprehensive analysis.

Swiss medical weekly·2025
Same author

Bridging the Milk Gap: Integrating a Human Milk Bank-Blood Bank Model to Reinforce Lactation Support and Neonatal Care.

Nutrients·2025
Same author

Severe Neonatal Anemia with Multi-Organ Failure, Extreme Placentomegaly, and Placental Megaloblastic Erythroblastosis as Features in Identifying Congenital Dyserythropoietic Anemia Type 1: A Case Report.

Neonatology·2025

Related Experiment Video

Updated: May 11, 2026

Collection of Alfalfa Root Exudates to Study the Impact of Di(2-ethylhexyl) Phthalate on Metabolite Production
06:46

Collection of Alfalfa Root Exudates to Study the Impact of Di(2-ethylhexyl) Phthalate on Metabolite Production

Published on: June 2, 2023

Phthalates in the NICU: is it safe?

Céline J Fischer1, Myriam Bickle Graz, Vincent Muehlethaler

  • 1Clinic of Neonatology, Department of Paediatrics, University Hospital of Lausanne.

Journal of Paediatrics and Child Health
|May 30, 2013
PubMed
Summary

Phthalate exposure from medical devices poses risks to hospitalized neonates, including developmental and reproductive issues. Clinicians should identify and replace di(2-ethylhexyl)phthalate-containing devices to protect vulnerable infants.

Keywords:
di(2-ethylhexyl)phthalate (DEHP)environmental exposureneonatal intensive care unit (NICU)newbornphthalatesplasticisersubfertility

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
08:08

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model

Published on: June 18, 2013

Related Experiment Videos

Last Updated: May 11, 2026

Collection of Alfalfa Root Exudates to Study the Impact of Di(2-ethylhexyl) Phthalate on Metabolite Production
06:46

Collection of Alfalfa Root Exudates to Study the Impact of Di(2-ethylhexyl) Phthalate on Metabolite Production

Published on: June 2, 2023

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
08:08

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model

Published on: June 18, 2013

Area of Science:

  • Neonatal Medicine
  • Toxicology
  • Medical Device Safety

Background:

  • Growing concerns surround phthalate exposure due to potential teratogenic, carcinogenic, and reproductive toxicity.
  • Medical devices frequently contain di(2-ethylhexyl)phthalate (DEHP), a common plasticizer.

Purpose of the Study:

  • To review evidence on the risks of di(2-ethylhexyl)phthalate exposure from medical devices in hospitalized neonates.
  • To inform clinicians about potential health dangers and guide safer clinical practices.

Main Methods:

  • Comprehensive literature review of medical databases including PubMed, MEDLINE, Cochrane, Embase, and Google Scholar.
  • Keywords used: phthalate, di(2-ethylhexyl)phthalate, newborn, and neonate.

Main Results:

  • Identified associations between phthalate exposure and adverse health outcomes in neonates.
  • Documented risks include subfertility, broncho-pulmonary dysplasia, necrotising enterocolitis, parenteral nutrition-associated cholestasis, and neurodevelopmental disorders.
  • Evidence primarily derived from animal and observational human studies.

Conclusions:

  • Clinicians must be aware of di(2-ethylhexyl)phthalate risks in the NICU.
  • Identification of DEHP-containing materials and consideration of alternative devices are recommended.
  • Further research is needed to improve understanding and management of phthalate exposure in neonates.